1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Xiamen Kingdomway Group Co. Class A

Xiamen Kingdomway Group Co. Class A

SSZSE:002626
18.65
CNY
+0.19
(+1.03%)
0.44EPS
29.05P/E
8.04BMarket Cap
Oct 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.15
1.47
2.14
2.83
3.39
4.64
5.17
5.74
5.91
4.91
5.05
5.31
5.54
5.67
Basic EPS, GAAP
0.18
0.34
0.2
0.51
0.77
1.11
0.73
1.57
1.29
0.42
0.45
0.56
0.56
0.45
Free Cash Flow per Basic Share
0.11
0.13
-1.14
0.6
0.66
1.3
1.2
1.18
0.82
0.87
0.66
0.26
0.54
- -
Dividend per Share
0.09
0.15
0.18
0.08
0.23
0.44
0.9
0.65
0.67
0.66
0.26
0.24
0.45
0.82
Book Value per Share
2.29
2.47
2.53
3.51
4.03
4.9
4.72
5.56
6.44
5.99
6.44
7.02
7.31
6.89
Tangible Book Value per Share
2.26
2.44
1.05
2.07
2.68
2.85
3.24
3.94
4.98
4.7
5.14
5.57
6.1
5.68
Basic Weighted Avg Shares
584
572
563
588
616
619
617
611
612
613
615
611
607
606
Sales/Revenue/Turnover
670
838
1,204
1,663
2,085
2,873
3,192
3,504
3,616
3,009
3,103
3,240
3,365
3,435
Operating Margin (%)
16.01
24.43
12.11
21.31
29.41
33.77
28.3
34.42
30.03
16.02
11.53
14.87
15.82
14.86
Depreciation Expense
38
50
72
88
83
98
120
112
179
207
209
205
209
- -
Net Income, GAAP
102
195
113
300
474
687
451
959
789
257
277
342
340
275
Effective Tax Rate (%)
14.07
15.78
16.13
17.36
17.62
17.73
25.82
16.78
16.04
21.11
17.46
21.83
15.13
15.79
Profit Margin (%)
15.24
23.21
9.35
18.03
22.74
23.92
14.12
27.37
21.81
8.55
8.92
10.55
10.1
8
Working Capital
773
863
316
1,042
1,256
1,060
1,157
973
1,469
1,089
1,381
1,446
2,725
2,051
LT Debt
- -
- -
289
380
334
734
776
681
896
467
653
715
1,693
1,523
Total Equity
1,317
1,421
1,541
2,180
2,491
3,021
2,955
3,492
4,027
3,665
3,936
4,318
4,496
4,308
Return on Invested Capital (%)
7.31
13.71
5.27
10.64
15.57
18.31
10.27
20.84
15.77
4.97
6.14
7.16
5.07
4.43
Return on Capital (%)
7.92
13.73
6.25
11.69
17.02
19.95
11.61
22.12
16.59
6.04
6.49
6.46
6.46
5.32
Return on Common Equity (%)
7.9
14.2
7.82
16.54
20.39
24.98
15.21
30.28
21.32
6.75
7.3
8.34
7.78
6.4

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
803
933
632
LT Borrowings
1,508
1,313
1,355
LT Finance Leases
185
171
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
610
610
610
Market Capitalization
12,022
10,698
8,039

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,024
3,816
3,191
Cash, Cash Equivalents & STI
2,560
2,379
1,712
Accounts Receivable, Net
370
388
429
Inventories
918
944
954
Total Current Liabilities
1,299
1,379
1,140
Payables & Accruals
- -
- -
- -
ST Debt
803
933
632
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.05%
5.51%
4.11%
Free Cash Flow
-5.3%
-0.12%
108.54%
Net Income, GAAP
29.31%
-10.93%
-0.61%
Sales/Revenue/Turnover
12%
-0.44%
3.87%
Total Cash Common Dividend
32.87%
4.31%
88.4%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
743
780
819
897
3,240
2025
827
901
- -
761
3,365
2026
813
960
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.1
0.15
0.2
0.56
2025
0.2
0.21
- -
-0.03
0.56
2026
0.11
0.17
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.21
0.02
- -
0.24
2025
0.02
0.41
- -
-0.02
0.45
2026
0.01
0.41
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bin Jiang
Full Time Employees
2,184
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 299 Yangguang West Road Xiamen FU China 361028
IPO Date
Oct 18, 2011
Website
kingdomway.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Xiamen Kingdomway Group Company, founded in 1997 and headquartered in Xiamen, China, operates primarily in the pharmaceutical and biotechnology sectors specializing in nutritional and pharmaceutical raw materials. Its core product portfolio includes coenzyme Q10, DHA, ARA, vitamin A, vitamin D3, vitamin K2, nattokinase, PQQ, NMN, astaxanthin, and pharmaceutical raw materials such as praziquantel, alanyl glutamine, and olacetam. The company is one of the world's top manufacturers of vitamin A and vitamin D3, supplying products internationally and operating state-of-the-art manufacturing facilities certified to GMP and ISO standards. Recent major developments include the strategic acquisition of Viactiv, a US-based nutritional supplements firm, for $17.2 million in 2024, marking Kingdomway's significant expansion into the international over-the-counter (OTC) health product market. The company also reported robust financial performance in 2024, with revenue reaching approximately RMB 3.24 billion, a year-on-year increase of 4.43%, driven by growth in its vitamin and nutritional product segments. Additionally, Xiamen Kingdomway continues to invest heavily in research and development, with a focus on expanding its pipeline of biopharmaceutical products and enhancing manufacturing capabilities while emphasizing sustainability goals and international market expansion. Xiamen Kingdomway serves global markets with a strong presence in North America, Europe, and Asia, targeting pharmaceutical companies, health product distributors, and consumers seeking high-quality nutritional supplements and pharmaceutical ingredients. The company maintains a commitment to innovation and quality assurance as essential pillars for its business growth and competitive positioning.